Silence Therapeutics plc is a biotechnology company specializing in the discovery and development of novel therapeutics using short interfering ribonucleic acid, or siRNA, to silence specific genes implicated in diseases with significant unmet medical needs. The company leverages its proprietary mRNAi GOLD™ platform to design siRNA molecules that harness the body’s natural RNA interference, or RNAi, mechanism, targeting messenger RNA to reduce the production of disease-associated proteins. This approach positions Silence Therapeutics at the forefront of RNAi-based drug development, focusing on rare and common diseases where existing treatments are limited or inadequate.

The company generates revenue primarily through collaborations and partnerships with pharmaceutical firms, which provide upfront payments, milestone payments, and potential royalties. Silence Therapeutics does not yet commercialize its own products, as its pipeline remains in preclinical and clinical development stages. Revenue streams include licensing agreements, option fees, and research milestones tied to the progression of its siRNA candidates through clinical trials. For example, partnerships with AstraZeneca and Hansoh have contributed upfront payments of $60 million and $16 million, respectively, alongside additional milestone payments as candidates advance.

The company operates through the following segments:

• Rare Diseases: This segment focuses on developing siRNA therapeutics for rare hematological and genetic disorders. The lead candidate, divesiran (SLN124), is in Phase 2 development for polycythemia vera, a rare blood cancer characterized by the overproduction of red blood cells. Divesiran silences the TMPRSS6 gene to elevate hepcidin levels, reducing iron availability and controlling red blood cell production. The segment also includes SLN548, a Phase 1-ready candidate targeting complement factor B for complement-mediated renal diseases.

• Cardiometabolic Diseases: This segment targets prevalent conditions such as cardiovascular disease and obesity. Zerlasiran (SLN360), a Phase 3-ready candidate, silences the LPA gene to lower lipoprotein(a), a genetically determined risk factor for cardiovascular events. SLN312, another candidate, targets ANGPTL3 to reduce cholesterol and triglycerides, while SLN365 and SLN098 address hypercholesterolemia and obesity, respectively. These programs aim to address large patient populations with high unmet needs.

Silence Therapeutics competes in the rapidly evolving RNAi therapeutics industry, where it faces competition from established biotechnology and pharmaceutical companies, as well as academic and research institutions. Key competitors include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Dicerna Pharmaceuticals, all of which are advancing RNAi-based therapies. The company’s competitive advantages lie in its proprietary mRNAi GOLD™ platform, which enables precise targeting of liver-expressed genes with durable and potent effects. Its focus on rare diseases and cardiometabolic conditions, coupled with orphan drug and Fast Track designations for divesiran, further strengthens its market position. However, the company’s success hinges on its ability to navigate clinical development, secure regulatory approvals, and forge commercial partnerships.

The company’s customer base consists primarily of pharmaceutical partners and, ultimately, patients suffering from rare and cardiometabolic diseases. Current collaborations include AstraZeneca and Hansoh, which have licensed or evaluated Silence Therapeutics’ siRNA candidates for further development. Once products receive regulatory approval, the company’s therapies will target patients with conditions such as polycythemia vera, elevated lipoprotein(a), hypercholesterolemia, and obesity. These patient populations span both rare and large-scale indications, offering significant commercial potential upon successful commercialization.